# Ibogaine Research Pilot Program One Step Closer to Reality After Committee Vote – Denver7 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ibogaine-research-pilot-program-colorado-advances/ > **Published:** 2026-03-26T11:05:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:56-04:00 > **Clinical Summary:** Colorado's ibogaine research pilot program advances, focusing on addiction treatment and cardiac safety in clinical investigation. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Psychedelics[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)Cardiac SafetySubstance Use Disorder Why This Matters Colorado’s ibogaine research pilot represents a significant step toward regulated clinical investigation of a psychedelic with documented but dangerous therapeutic potential. This matters because ibogaine shows promise for [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) but carries serious cardiac risks that have prevented widespread clinical adoption. Clinical Summary Ibogaine is a naturally occurring psychoactive compound derived from the African shrub Tabernanthe iboga, with documented effects on addiction pathways through interactions with multiple neurotransmitter systems including dopamine, serotonin, and NMDA receptors. Clinical reports suggest potential efficacy for opioid use disorder, but ibogaine is associated with serious cardiac arrhythmias and sudden death, particularly QT prolongation. Current therapeutic use occurs primarily in unregulated international settings. Colorado’s proposed pilot program would establish controlled research conditions to evaluate both efficacy and safety protocols. Dr. Caplan’s Take “I’ve seen too many patients seek ibogaine treatment abroad in uncontrolled settings because of desperation with treatment-resistant addiction. If we can study this systematically with proper cardiac monitoring and medical oversight, we might finally get real answers about whether the benefits justify the very real risks.” Clinical Perspective 🧠 Clinicians should understand that ibogaine remains investigational and carries significant cardiovascular contraindications, particularly for patients with existing heart conditions or those taking medications affecting cardiac conduction. Any future therapeutic protocols will likely require comprehensive cardiac screening and continuous monitoring. Patients expressing interest should be counseled about current risks and advised to participate only in properly supervised clinical settings when available. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Ibogaine%20research%20pilot%20program%20one%20step%20closer%20to%20reality%20after%20committee%20vote%20...%20%40drcaplan&url=https%3A//www.denver7.com/news/politics/ibogaine-research-pilot-program-in-colorado-moves-one-step-closer-to-reality-after-committee-vote-of-approval)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.denver7.com/news/politics/ibogaine-research-pilot-program-in-colorado-moves-one-step-closer-to-reality-after-committee-vote-of-approval)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Ibogaine%20research%20pilot%20program%20one%20step%20closer%20to%20reality%20after%20committee%20vote%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.denver7.com/news/politics/ibogaine-research-pilot-program-in-colorado-moves-one-step-closer-to-reality-after-committee-vote-of-approval)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.denver7.com/news/politics/ibogaine-research-pilot-program-in-colorado-moves-one-step-closer-to-reality-after-committee-vote-of-approval](https://www.denver7.com/news/politics/ibogaine-research-pilot-program-in-colorado-moves-one-step-closer-to-reality-after-committee-vote-of-approval) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this research?](#What_is_the_clinical_relevance_rating_of_this_research) - [What medical fields does this research cover?](#What_medical_fields_does_this_research_cover) - [Why is cardiac safety highlighted in this psychedelics research?](#Why_is_cardiac_safety_highlighted_in_this_psychedelics_research) - [How does this relate to addiction medicine?](#How_does_this_relate_to_addiction_medicine) - [What should clinicians know about this development?](#What_should_clinicians_know_about_this_development) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this research? This study has been assigned a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This means the findings represent emerging developments or policy changes that warrant close monitoring by [healthcare professionals](https://cedclinic.com/women-reproductive-health-cannabis-applications/). #### What medical fields does this research cover? The research spans multiple medical disciplines including psychedelics, [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/), and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). There is also a focus on cardiac safety considerations, suggesting cardiovascular monitoring may be important. #### Why is cardiac safety highlighted in this psychedelics research? Cardiac safety is flagged as a key consideration because many psychedelic compounds can affect heart rhythm and blood pressure. This makes cardiovascular monitoring essential during treatment, especially in patients with pre-existing heart conditions. #### How does this relate to addiction medicine? The research appears to explore psychedelics as potential treatments for addiction disorders. This represents an emerging therapeutic approach that could offer new options for patients with [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/). #### What should clinicians know about this development? Clinicians should monitor these emerging findings as they may influence future treatment protocols for addiction medicine. The cardiac safety component suggests that proper patient screening and monitoring protocols will be essential if these treatments advance to [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Ibogaine research pilot program one step closer to reality after committee vote – Denver7”, “url”: “https://www.denver7.com/news/politics/ibogaine-research-pilot-program-in-colorado-moves-one-step-closer-to-reality-after-committee-vote-of-approval”, “datePublished”: “2026-03-26T09:31:10Z”, “about”: “ibogaine research pilot program one step”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Plans To Sign Executive Order On The Psychedelic Ibogaine As Soon As This Week …](https://cedclinic.com/ibogaine-opioid-use-disorder-treatment-executive-order/) Stay updated on federal regulatory changes impacting ibogaine research and clinical use with the latest executive order developments. [Read More](https://cedclinic.com/ibogaine-opioid-use-disorder-treatment-executive-order/) [A New Take on the Antidepressants vs Psychedelics Efficacy Debate – Drug Science](https://cedclinic.com/psychedelic-therapies-for-depression-efficacy-debate/) Explore the evolving evidence comparing psychedelic therapies like ibogaine with traditional antidepressants for mental health treatment. [Explore Insights](https://cedclinic.com/psychedelic-therapies-for-depression-efficacy-debate/) Fast-Tracking Psychedelics Research – YouTube Watch expert discussions on accelerating clinical research for psychedelics including ibogaine and their potential therapeutic roles. Watch Now ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).